Comparing the current results to its competitors, Burning Rock Biotech Limited reported Revenue increase in the 4 quarter 2025 by 9.18 % year on year. The revenue growth was below Burning Rock Biotech Limited's competitors' average revenue growth of 17.34 %, achieved in the same quarter.
Burning Rock Biotech Limited's Comment on Competition and Industry Peers
The company is a leading provider of next-generation sequencing (NGS)-based cancer therapy selection services in China, operating within the competitive cancer genotyping industry. Its primary competitors include domestic NGS-based cancer therapy selection and minimal residual disease (MRD) companies such as AmoyDx, BGI, and Geneseeq. These competitors may possess advantages in areas such as expertise, experience, financial resources, business relationships, technology maturity, market adoption, test menu breadth, or brand recognition. The company recognizes the risk of its technologies becoming obsolete if it does not keep pace with industry developments.
May 30, 2024
In today s era of advanced healthcare, precision medicine has emerged as a game-changer in the treatment of cancer. The efficient matching of patients with personalized therapies has the potential to revolutionize outcomes. In a significant development, pharmaceutical giant Bayer and precision oncology company Burning Rock have joined hands to enhance patient access to precision cancer medicines. This collaboration brings together the expertise of both companies to tackle the rising global cancer burden.Outline of Facts:1. Bayer and Burning Rock s Collaborative Efforts:Bayer, a renowned multinational pharmaceutical company committed to advancing healthcare solutions, has entered into a collaboration with Bur...
Publicly Traded Peers of Burning Rock Biotech Limited
Biodesix Inc Share Performance
+24.27%
30 Days
Biodesix Inc
Profile
Biodesix Inc is a biotechnology company that utilizes advanced diagnostics to develop personalized medicine solutions for improving patient outcomes. Their business model involves leveraging their proprietary blood-based tests and data analytics to assist healthcare providers in making informed treatment decisions. By partnering with pharmaceutical companies and healthcare institutions, Biodesix aims to commercialize their innovative solutions and drive adoption in the healthcare industry.
Sera Prognostics Inc has a business model that focuses on developing and commercializing innovative diagnostic tests for predicting pregnancy complications.
Veracyte Inc's business model revolves around providing genomic diagnostic solutions to enable physicians to make more informed treatment decisions for patients.
Exact Sciences Corporation is a medical diagnostics company that specializes in early cancer detection. Their business model involves developing and commercializing non-invasive, DNA-based tests for the detection of colorectal cancer, as well as other cancers and diseases. By leveraging advanced technology and partnerships with healthcare providers, Exact Sciences aims to improve patient outcomes through early detection and intervention.
Fortrea Holdings Inc is a company that operates through its subsidiaries in the business of software and technology services, providing innovative solutions and products to its clients. Its business model focuses on developing and delivering custom software applications, digital platforms, and consulting services to cater to the specific needs of various industries.
Sources:
Burning Rock Biotech Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Burning Rock Biotech Limited versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
